caa a22 4500 469121718 CHVBK 20180323133140.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF02246238 doi (NATIONALLICENCE)springer-10.1007/BF02246238 Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo [Elektronische Daten] [J. Ramaekers, H. Swijgman, J. O'Hanlon] The acute and sub-chronic effects of moclobemide and mianserin on driving and psychometric performance were compared to those of placebo in a double-blind, cross-over study involving 17 healthy volunteers. Mianserin, moclobemide and placebo were administered for 8 days. Subjects' performance was measured on days 1 and 8 of each treatment series; subjective sleep parameters, mood, and possible side-effects were recorded each treatment day on questionnaires or visual analog scales. Mianserin affected most of the performance measures, while moclobemide affected none; mianserin also impaired driving and tracking performance and decreased CFF. Whilst receiving mianserin, subjects reported depressed levels of alertness, calmness, and contentment; the quality of their sleep was unaffected, but its duration increased, together with feelings of drowsiness and fatigue during the day. No statistical interactions between the factors Drugs and (Treatment) Days were found, indicating that little pharmacological tolerance developed over time during mianserin treatment. Mianserin's sedative properties are held responsible for all performance and subjective effects of the drug. It is concluded that moclobemide 200 mg b.i.d. has no important sedative properties. Springer-Verlag, 1992 Moclobemide nationallicence Mianserin nationallicence Driving performance nationallicence Psychometric performance nationallicence Subjective assessments nationallicence Ramaekers J. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut Swijgman H. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut O'Hanlon J. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut Psychopharmacology Springer-Verlag 106(1992-02-01), S62-S67 0033-3158 106<S62 1992 106 213 https://doi.org/10.1007/BF02246238 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02246238 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ramaekers J. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Swijgman H. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- O'Hanlon J. Institute for Drugs, Safety and Behaviour, University of Limburg, Beeldsnijdersdreef 85, NL-6216 EA, Maastricht, The Netherlands aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106(1992-02-01), S62-S67 0033-3158 106<S62 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer